1. Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid.
- Author
-
Takayama N, Sato N, O'Brien SG, Ikeda Y, and Okamoto S
- Subjects
- Adult, Antineoplastic Agents blood, Antineoplastic Agents cerebrospinal fluid, Benzamides, Blood-Brain Barrier, Central Nervous System Neoplasms blood, Central Nervous System Neoplasms cerebrospinal fluid, Enzyme Inhibitors blood, Enzyme Inhibitors cerebrospinal fluid, Female, Humans, Imatinib Mesylate, Piperazines blood, Piperazines cerebrospinal fluid, Precursor Cell Lymphoblastic Leukemia-Lymphoma blood, Precursor Cell Lymphoblastic Leukemia-Lymphoma cerebrospinal fluid, Pyrimidines blood, Pyrimidines cerebrospinal fluid, Antineoplastic Agents therapeutic use, Central Nervous System Neoplasms drug therapy, Enzyme Inhibitors therapeutic use, Piperazines therapeutic use, Precursor Cell Lymphoblastic Leukemia-Lymphoma drug therapy, Pyrimidines therapeutic use
- Abstract
A 32-year-old woman with relapsed Philadelphia chromosome-positive acute lymphoblastic leukaemia was treated with imatinib mesylate (formerly STI571), a selective inhibitor of BCR/ABL tyrosine kinase. Although the initial marrow response was good and stably maintained, she subsequently relapsed with extensive infiltration of leukaemic cells into the central nervous system (CNS). After controlling her CNS disease with additional intrathecal chemotherapy, we measured the concentration of imatinib in cerebrospinal fluid (CSF) and blood simultaneously. The concentration of imatinib in CSF was about 92-fold lower than that in blood. These results suggest that imatinib poorly penetrates the blood-brain barrier and has limited activity against CNS leukaemia.
- Published
- 2002
- Full Text
- View/download PDF